| All Releases |
|---|
 |
Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
03/10/10
|
11.2 KB
|
| |
CORAL GABLES, Fla., March 10, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Catalyst's Chief Executive Officer, will be making a presentation at the BioNetwork East 2010 Conference to be held March 15th through March 17th at the Eden Roc Resort and Spa on Miami ...
|
|
|
Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
02/25/10
|
11.6 KB
|
| |
CORAL GABLES, Fla., Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it will be making a presentation today at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum being held at the Hyatt Embarcadero Hotel in San Francisco. For additional program inform...
|
|
|
Catalyst Pharmaceutical Partners and The National Institute on Drug Abuse Plan to Initiate U.S. Phase II(b) Clinical Trial for Cocaine Addiction
02/23/10
|
13.1 KB
|
| |
CORAL GABLES, Fla., Feb 23, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, fo...
|
|
|
Catalyst Pharmaceutical Partners to Discuss Development Plans for CPP-115 on February 23, 2010 Conference Call
02/22/10
|
18.7 KB
|
| |
CORAL GABLES, Fla., Feb 22, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) will hold a conference call on Tuesday, February 23, 2010 to discuss its initial development plans for CPP-115. Patrick J. McEnany, Catalyst Pharmaceutical's Chief Executive Officer, will host the call.
CPP-115 is a compo...
|
|
|
Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
02/17/10
|
15.7 KB
|
| |
CORAL GABLES, Fla., Feb 17, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held Feb...
|
|
|
Catalyst Receives Guidance from Nasdaq Regarding Minimum Bid Price Requirement
11/13/09
|
12.3 KB
|
| |
CORAL GABLES, Fla., Nov 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it received a Nasdaq Staff Deficiency Letter dated November 13, 2009 indicating that the Company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule ...
|
|
|
Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
11/12/09
|
16.7 KB
|
| |
CORAL GABLES, Fla., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) today reported financial results for the third quarter and nine months ended September 30, 2009.
Third Quarter 2009 ResultsFor the quarter ended September 30, 2009, the Company reported a net loss of $1,286,720...
|
|
|
U.S. Department of Defense Awards $1.2 Million to Study the Use of Vigabatrin to Reduce the Addictive Liability of Opiates While Still Effectively Managing Pain
11/10/09
|
16.0 KB
|
| |
CORAL GABLES, Fla., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) today reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a $1.2 million grant from the U.S. Department of D...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executive's Employment Agreement
10/13/09
|
13.2 KB
|
| |
CORAL GABLES, Fla., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced two organizational changes and the extension of the term of Patrick J. McEnany's employment agreement with the Company for an additional two years.
Organizational ChangesThe Company announced that...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
10/06/09
|
12.5 KB
|
| |
CORAL GABLES, Fla., Oct 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that it has closed its previously announced registered direct offering of 3.97 million shares of its common stock to institutional investors at a price per share of $1.00, representing gross procee...
|
|
|
Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10/01/09
|
13.8 KB
|
| |
CORAL GABLES, Fla., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that it has entered into definitive agreements to sell 3.97 million shares of its common stock at a price per share of $1.00 pursuant to a registered direct offering to several select institutiona...
|
|
|
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
09/30/09
|
18.4 KB
|
| |
CORAL GABLES, Fla., Sept 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction. The Company's decision was made after, and based up...
|
|
|
Catalyst Pharmaceutical Partners To Transfer To NASDAQ Capital Market
09/02/09
|
11.0 KB
|
| |
CORAL GABLES, Fla., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) has received approval from The NASDAQ Stock Market to transfer the listing of its common stock from The NASDAQ Global Market(R) to The NASDAQ Capital Market(R). The transfer will be effective at the opening of t...
|
|
|
Catalyst Pharmaceutical Partners Licenses Exclusive Rights to New Class of GABA Aminotransferase Inhibitors From Northwestern University
08/31/09
|
15.2 KB
|
| |
CORAL GABLES, Fla., Aug 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that the Company executed a license agreement under which it acquired exclusive worldwide rights to commercialize novel GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by...
|
|
|
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
08/07/09
|
18.5 KB
|
| |
CORAL GABLES, Fla., Aug 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the second quarter and six months ended June 30, 2009.
Second Quarter 2009 Results
For the quarter ended June 30, 2009, the Company reported a net loss of $1,761,887, or $0.1...
|
|
|
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
05/29/09
|
14.8 KB
|
| |
CORAL GABLES, Fla., May 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint ...
|
|
|
Catalyst Pharmaceutical Partners Receives NASDAQ Deficiency Notice
05/22/09
|
13.0 KB
|
| |
CORAL GABLES, Fla., May 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on May 19, 2009 it was advised by The NASDAQ Stock Market(R) that, based on the Company's stockholders equity as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended M...
|
|
|
Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results
05/14/09
|
15.9 KB
|
| |
CORAL GABLES, Fla., May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the first quarter ended March 31, 2009.
First Quarter 2009 Results
For the quarter ended March 31, 2009, the Company reported a net loss of $3,031,201, or $0.22 per basic and...
|
|
|
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
03/27/09
|
17.4 KB
|
| |
CORAL GABLES, Fla., March 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended...
|
|
|
Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction
03/03/09
|
13.7 KB
|
| |
CORAL GABLES, Fla., March 3, 2009 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced modifications to its previously announced product development p...
|
|
|
